These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Triple-drug therapy may mean lifelong commitment.
    Journal: AIDS Alert; 1999 Jan; 14(1):3-5. PubMed ID: 11366090.
    Abstract:
    Recent U.S. and French studies indicate that antiretroviral therapy that includes three or more drugs will need to be continued indefinitely for viral suppression to be maintained. These studies used combinations of Indinavir (Crixivan), Zidovudine (AZT), and Lamivudine (Epivir). Triple-drug therapy requires that patients take five or more pills two or three times a day, which is a challenging regimen to follow. The AIDS Clinical Trials Group Study 343 found that when patients on triple-drug combinations changed to two drugs or monotherapy, the virus rebounded in a significant number of patients. The idea of putting people on aggressive treatment early on in the disease is now being challenged by many researchers and clinicians.
    [Abstract] [Full Text] [Related] [New Search]